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Introduction
Mast cells (MCs) are bone marrow derived cells char-
acterized by their sensitivity to IgE-dependent stimulation 
and unique cytoplasmic granule contents, such as histamine, 
tryptase, chymase. MCs intricately associate with blood ves-
sels and nerves in most vertebrates. They are frequent at sites 
that interface with the external environment such as the skin, 
respiratory and gastrointestinal tracts. As front-line cells at 
the host-environment interfaces, MCs promote host defense 
against pathogens by facilitating the initiation of appropriate 
immune responses. MCs are renowned contributors to hy-
persensitivity reactions and participate in tissue remodeling 
events and are considered pro-angiogenic, promoting vessel 
formation through both constitutive and immunologically 
mediated release of angiogenic substances [1].
The contribution of MCs to tumor development and pro-
gression has proven to be a controversial area of research. 
Clinical studies have suggested a link between elevated IgE 
or the presence of allergic disease and reduced development 
of melanoma, breast cancer, and some types of brain tumor 
[2]. The ability of MCs to promote angiogenesis is viewed as 
a key process in promoting tumor development [3].
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Abstract
Background: Tumor growth and development is determined by the mutual interaction between the cancer cells themselves and the microenvironment. 
It contains various elements, including immune cells. Of all, mast cells have one of the most controversial roles. The aim of the present study was to 
evaluate the expression of mast cell tryptase in the luminal and non-luminal subtypes of breast cancer and establish a possible link between infiltration 
with MCs and expression of hormone receptors.
Material and methods: The experimental study included 80 cases of breast carcinomas that were analyzed immunohistochemically in order to establish 
the molecular profile and the expression of tryptase, a specific marker of mast cells. The data were processed using the SPSS program. Pearson’s coefficient 
(r) and the other values were considered statistically significant in case of p≤0.05.
Results: Both intratumoral mast cells (MCit) and peritumoral mast cells (MCpt) correlated with the expression of hormone receptors for estrogen (ER) 
and progesterone (PR). Thus, the following relations were established: MCit and ER (r=0.343, p=0.002), MCpt and ER (r=0.394, p=0.000295) and MCpt 
and PR (r=0.386, p=0.000409). Statistically significant correlations between HER2 expression and mast cells content have not been established.
Conclusions: Mast cells invasion, peri- and intratumoral, is strongly influenced by the expression of hormone receptors. The luminal subtypes of breast 
cancer are characterized by a higher density of mast cells. 
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MCs infiltrations have been described in a variety of hu-
man cancers, including non-small-cell lung cancer and pul-
monary adenocarcinoma [4], breast cancer [5], colorectal 
cancer [6], and basal cell carcinoma [7]. Several studies have 
reported links between disease progression and survival and 
MC density [1, 8]. It has been proposed that MCs could dis-
play a protective effect before tumor onset, but sustain its 
development at later stages [9]. Tryptase, the most abundant 
secretory granule-derived neutral serine proteinase con-
tained in MCs, can degrade components of the extracellular 
matrix and has been used as a specific marker for MCs [10]. 
Tryptase+ MCs are often observed in peritumoral areas in 
early-stage breast cancers without evidence of degranulation 
[1]. Historically, MC tryptase is renowned for its pro-tumor-
igenic role via enhancement of angiogenesis [11]. 
Some MCs proteases are stored in complexes with hepa-
rin. Heparin suppresses proliferation and reduces the num-
ber of breast cancer cell colonies. It was hypothesized that 
heparin might interrupt interactions between tumor-associ-
ated fibroblasts and cancer cells, thus impairing tumor de-
velopment. Some scholars noticed that Mcs are enriched in 
the tumor bed and invasive margin of late-stage breast can-
cers, especially in case of luminal subtypes [12]. In breast 
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cancer, as in cutaneous human tumors, the local impact of 
MCs on tissue remodeling and cell recruitment events, and 
their effect on draining lymph nodes/systemic immunity 
need to both be carefully considered and may not have simi-
lar disease impacts [1].
The aim: Evaluation of the expression of mast cell trypt-
ase in the luminal and non-luminal subtypes of breast can-
cer and establishing a possible link between infiltration with 
MCs and expression of hormone receptors.
Material and methods
This study included patients with breast carcinomas who 
were treated by surgery at Arad Clinical Hospital, Romania 
during 2013-2016. The patients did not undergo chemo- or 
radiotherapy before surgery. 
The histological technique was described in the previ-
ous work which also regarded MCs [13]. All samples were 
routinely processed: fixed in 10% formalin and embedded in 
paraffin (Paraplast High Melt, Leica Biosystems). The blocks 
were then used to create tissue microarrays by TMA Grand 
Master (3DHISTECH Ltd., Budapest, Hungary) and cut 
into 4-μm-thick sections which were placed on glass slides 
(Surgipath X-tra Adhesive, Leica Biosystems, Newcastle 
UponTyne, UK). The sections were automatically colored us-
ing Mayer’s hematoxylin (Merck, Germany), aqueous eosin 
(Merck, Germany) and analyzed by 3 independent patholo-
gists. The appropriate cases were selected for immunohisto-
chemical staining.
Immunohistochemistry for estrogen receptor (ER), pro-
gesterone receptor (PR), HER2 and tryptase was performed 
automatically by Leica Bond-Max (Leica Biosystems, 
Newcastle UponTyne, UK) in order to establish the molec-
ular subtype and to detect the MCs. Antigen retrieval was 
performed by incubating the slides in the Bond Epitope 
Retrieval Solution 1 (pH 6) and 2 (pH 9) (Leica Biosystems, 
Newcastle UponTyne, UK). Primary antibodies used in this 
study were the following: PR (clone 16), ER (clone 6F11), 
mast cell tryptase (10D11) and HER2 (clone CB11), all from 
Leica Biosystems (Newcastle UponTyne, UK), and all ready-
to-use. The Bond Epitope Retrieval Solution 2, pH9, Leica 
Biosystems (Newcastle UponTyne, UK) was applied for 20 
minutes and time of incubation was 30 minutes. The system 
of detection was Bond Polymer Refine Detection System. 
Mayer’s hematoxylin was used for counterstaining (5 minu-
tes).
ER, PR and HER2 scoring was done by standard meth-
od (according to Allred score and according to the recom-
mendations of the American Society of Clinical Oncology, 
respectively) [14, 15]. The cut-off for ER and PR was 10%. 
The cases were classified into molecular subtypes as follows: 
luminal A (ER+ and/or PR+, HER2−), luminal B/ HER2− 
(ER+, HER2− with PR <20%/or PR-), luminal B/HER2+ 
(ER+ and/or PR+, HER2+), HER2+ (ER− and PR−/HER2+), 
and triple-negative breast cancer (ER−/PR−/HER2−) [12].
The slides stained for tryptase were scanned on Axio 
Imager A2 microscope (Carl Zeiss, Germany) at low mag-
nification (×100), and the areas with the highest number of 
positive cells were chosen. The number of MCs located in 
the tumor and peritumoral stroma was counted. Mast cells 
were subdivided into intratumoral (MCit) and peritumoral 
(MCpt). There were analyzed 3 microscopic fields for each 
type of localization, at ×400 magnification. 
Data was stored in a MS Excel 2010 database and ana-
lyzed statistically by the SPSS statistical software package 
(SPSS Statistics 23.0; IBM, Chicago, IL, USA). Pearson’s co-
efficient and other values were considered statistically sig-
nificant in case of p≤0.05.
Results
80 cases of breast carcinomas were analyzed. The mean 
age of patients was 66.04, ranging from 37 to 84. Most tu-
mors were moderately differentiated (45 cases). There was 
found only one well differentiated case and 34 were poorly 
differentiated. According to the histological type, 74 cases 
(92.5%) were ductal invasive, 3 cases (3.8%) – lobular inva-
sive, 2 cases (2.5%) – lobular in situ and 1 case (1.3%) – duc-
tal in situ. The most frequent molecular subtype was luminal 
B/HER2+ (fig. 1).
Fig.1. the distribution of molecular subtypes, n=80
Then was analyzed the distribution of MCs in different 
molecular subtypes. Higher numerical values of both MCit 
and MCpt were determined in luminal subtypes (tab. 1).




Luminal B/HER2+ 27.6 65.0
Luminal A 20.0 27.6
HER2+ 6.0 11.3
Triple-negative 2.3 16.6
These data were also supported by statistically significant 
correlations. Both MCit and MCpt correlated with the ex-
pression of hormone receptors for estrogen and progester-
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one. Thus, the following relations were established: MCit and 
ER (r=0.343, p=0.002), MCpt and ER (r=0.394, p=0.000295) 
and MCpt and PR (r=0.386, p=0.000409). Moreover, statisti-
cally significant correlations between HER2+ expression and 
MCs have not been established (MCit and HER2+: r=-0.026, 
p=0.820; MCpt and HER2+: r=0.199, p=0.077).
Mann-Whitney U test was done to compare MCit and 
MCpt in luminal and non-luminal subtypes. Its results sup-
ported the previous findings (tab. 2 and 3).
table 2. the differences between MCit and MCpt in 









































Tumor growth and development are determined by both, 
cancer cell–autonomous and microenvironmental mecha-
nisms, including the contribution of infiltrating immune 
cells and the complexity of these phenomena is well recog-
nized [4, 8, 9]. Of all, MCs have one of the most controversial 
roles.
Thus, several lines of evidence suggest that MCs are re-
sponsible for mediating angiogenesis [1, 16, 17]. Imada A. et 
al. compared survivals in the low and high MC count groups 
in patients with stage I lung adenocarcinoma. The members 
in the high MC count group had significantly worse prog-
nosis than those in the low mast cell count group (p<0.05). 
In the well- and moderate-differentiation subgroups of lung 
adenocarcinoma, members in the high MC count group had 
extremely significantly worse prognosis than those in the 
low MC count group (p<0.01) [4]. Suzuki S. et al. concluded 
that high peritumoral MCs infiltration predicts poor prog-
nosis in patients who underwent hepatectomy for colorectal 
liver metastases. The number of MCs in metastatic lesions 
is important for predicting the prognosis of colorectal liver 
metastases patients and as an indication of therapy [11]. 
Hu G. et al. showed in a meta-analysis including 28 published 
studies with 4224 patients identified from PubMed and EBSCO 
that tryptase+ MC infiltration significantly decreased overall 
survival and disease-free survival in all types of solid tumors 
and significantly correlated with lymph node metastasis of 
solid tumor [10].
However, elevated MCs at tumor sites or within draining 
lymph nodes have also been connected with improved out-
comes [1]. Rajput AB. et al. conducted a study on tissue mi-
croarrays containing 4.444 cases and showed that the pres-
ence of stromal MCs was a favorable prognostic factor in the 
training set (p=0.001) [18]. Similar to our findings, Majorini 
MT. et al. proved that MCs influence the phenotype of breast 
cancer cells by stimulating a luminal phenotype which has 
a better outcome. They increased expression of ER, PGR, 
BCL2, and CK8. Simultaneously, MCs reduce the activation 
of HER2 and basal drivers such as EGFR, and prevent the 
expression of the basal marker CK5, thus potentially affect-
ing the behavior of neighboring cancer cells [9].
Conclusions
Mast cells invasion, peri- and intratumoral, is strongly 
influenced by the expression of hormone receptors. The lu-
minal subtypes of breast cancer are characterized by a higher 
density of mast cells.
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